Investor Moves
News
businesswire.comVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancerbusinesswire.comApr 13
defenseworld.netPark Avenue Securities LLC Sells 37,510 Shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTENdefenseworld.netMar 22